Semaglutide and the Skin: An Overview of Current Evidence
DOI:
https://doi.org/10.12775/QS.2026.50.67988Keywords
semaglutide, GLP-1 receptor agonists, skinAbstract
Background. Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1. GLP-1 plays a role in the physiological regulation of appetite and energy intake.
Aim. This review summarizes current evidence on the effects of semaglutide on skin conditions and its cutaneous adverse reactions.
Materials and methods. A literature search was conducted in PubMed and Google Scholar databases using the keywords: “semaglutide”, “skin”, “glp-1 receptor agonists”, “dermatology”. Meta-analyses, systematic reviews, original studies, clinical trials, case series, and case reports in English were included without time restrictions. Eligible studies involved human subjects and provided data on semaglutide’s effects on skin diseases and/or cutaneous side effects. Reference lists were also screened for additional relevant articles.
Results. Available literature indicates potential therapeutic benefits of semaglutide in several skin disorders, including hidradenitis suppurativa and psoriasis. However, reports of cutaneous adverse reactions and newly emerging skin conditions have also been documented.
Conclusions. Semaglutide may offer therapeutic value in dermatological conditions such as psoriasis and hidradenitis suppurativa, however cutaneous adverse reactions have also been reported. Further research is required to clarify its clinical utility and safety profile in dermatology.
References
1. Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use: full prescribing information [Internet]. U.S. Food and Drug Administration; 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf
2. Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use: full prescribing information [Internet]. U.S. Food and Drug Administration; 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
3. Anastasiou IA, Tentolouris A, Sarantis P, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025;17(9):1115. https://doi.org/10.3390/pharmaceutics17091115
4. Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455-456; 457-472. https://doi.org/10.1111/j.1600-0625.2008.00712_1.x
5. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9-16. https://doi.org/10.4161/derm.2.1.12490
6. Krajewski PK, Złotowska A, Szepietowski JC. The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects. J Clin Med. 2024;13(21):6292. https://doi.org/10.3390/jcm13216292
7. Gupta R, Cesar L, Micheletti R, Fang V. Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity. JAAD Int. 2025;21:40-43. https://doi.org/10.1016/j.jdin.2025.05.004
8. Hill MA, Bordeaux JS. Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX. J Am Acad Dermatol. 2025;92(4):896-897. https://doi.org/10.1016/j.jaad.2024.11.039
9. Posada Posada MI, Alora MB, Lima XTV. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025;39(8):e662-e664. https://doi.org/10.1111/jdv.20392
10. Lyons D, Louly Nathan A, Pender E, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631-633. https://doi.org/10.1093/bjd/ljae216
11. Islam RK, Malek AJ, Langley CT, Islam KN, Haas CJ. A-MACE-Ing: A Real-World Analysis of Semaglutide’s Impact on Major Adverse Cardiovascular Events (MACE) in Patients With Hidradenitis Suppurativa. Int J Dermatol. Published online July 14, 2025. https://doi.org/10.1111/ijd.17910
12. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. https://doi.org/10.1038/nrdp.2016.82
13. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-1204. https://doi.org/10.1016/S0140-6736(03)12954-6
14. Petković-Dabić J, Binić I, Carić B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025;15(1):46. https://doi.org/10.3390/biom15010046
15. Nicolau J, Nadal A, Sanchís P, et al. Dermatologic and Metabolic Benefits of Semaglutide in Psoriasis with Obesity: A Six-Month Prospective Cohort Study. Clin Exp Dermatol. Published online October 25, 2025. https://doi.org/10.1093/ced/llaf473
16. Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. Published online August 1, 2021. https://doi.org/10.1530/EDM-21-0007
17. Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. https://doi.org/10.1530/EDM-23-0017
18. Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153-e154. https://doi.org/10.1111/jdv.20197
19. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141-1143. https://doi.org/10.1016/j.jaad.2025.01.046
20. Nakhla M, Nair A, Balani P, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovasc Drugs Ther. 2025;39(6):1331-1341. https://doi.org/10.1007/s10557-024-07613-w
21. Levy S, Attia A, Elshazli RM, et al. Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. Cancers (Basel). 2024;17(1):78. https://doi.org/10.3390/cancers17010078
22. Castellanos V, Workneh H, Malik A, Mehta B. Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement. Cureus. 2024;16(3):e55324. https://doi.org/10.7759/cureus.55324
23. Chen H, Elhawi M, Tarbox M. The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma. Cureus. 2025;17(7):e88725. https://doi.org/10.7759/cureus.88725
24. Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. J Am Acad Dermatol. 2024;91(1):166-168. https://doi.org/10.1016/j.jaad.2024.03.021
25. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. https://doi.org/10.1016/S0140-6736(23)01185-6
26. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. https://doi.org/10.1001/jama.2021.1831
27. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. https://doi.org/10.1016/S2213-8587(17)30013-X
28. Feinstein J, Hajirawala M, Jalali J, Wild L. THE FIRST REPORT OF ANGIOEDEMA AND ANAPHYLAXIS WITH TEMPORAL ASSOCIATION TO SEMAGLUTIDE. Annals of Allergy, Asthma & Immunology. 2022;129(5):S85. https://doi.org/10.1016/j.anai.2022.08.735
29. Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Rep. 2021;15:107-109. https://doi.org/10.1016/j.jdcr.2021.07.027
30. Ouellette S, Frias G, Shah R, Alamgir M, Wassef C. Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports. J Drugs Dermatol. 2023;22(4):413-416. https://doi.org/10.36849/JDD.6550
31. Posso-Osorio I, Vargas-Potes CJ, Mejía M, Cañas CA. Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature. Clin Rheumatol. 2023;42(9):2501-2506. https://doi.org/10.1007/s10067-023-06612-w
32. Farasat S, McCallum J. Semaglutide-induced leukocytoclastic vasculitis. Endocrine Practice. 2022;28(5, Supplement):S21-S22. https://doi.org/10.1016/j.eprac.2022.03.067
33. Pinheiro MM, de Souza LG, Nunes GP, et al. The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. Curr Med Res Opin. 2024;40(9):1525-1531. https://doi.org/10.1080/03007995.2024.2386047
34. Stark J, Klass MJ, Owen L. Allodynia (skin tenderness) associated with semaglutide: A case series. Am J Health Syst Pharm. 2025;82(9):e426-e430. https://doi.org/10.1093/ajhp/zxaf008
35. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. https://doi.org/10.1177/20420188231222367
36. Mintoff D, Agius R, Fava S, Pace NP. Investigating Adiposity-Related Metabolic Health Phenotypes in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study. J Clin Med. 2023;12(14):4847. https://doi.org/10.3390/jcm12144847
37. Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa ?-15 years after. Exp Dermatol. 2020;29(12):1154-1170. https://doi.org/10.1111/exd.14214
38. Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GBE. Risk factors, clinical course and long‐term prognosis in hidradenitis suppurativa: a cross‐sectional study. Br J Dermatol. 2014;171(4):819-824. https://doi.org/10.1111/bjd.13090
39. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. https://doi.org/10.1038/nutd.2012.26
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Natalia Gołąbek, Łukasz Szymański, Milena Mordarska, Artur Merc, Przemysław Piątek, Alicja Kodura, Alicja Piwowarczyk, Jan Łozowski, Joanna Paluchowska, Julia Białas
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 31
Number of citations: 0
